Recent advances in the management of multiple myeloma

National Medical Journal of India

Volumn 23, Issue 4, 2010, Pages 210-218

  Kumar, Lalit ^a,b   Verma, Rakesh ^a,b   Radhakrishnan, Venkat Raman ^a,b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b Department of Medical Oncology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IRON; LENALIDOMIDE; M PROTEIN; MELPHALAN; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; PARAPROTEIN; POMALIDOMIDE; PREDNISONE; SALINOSPORAMIDE A; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALOPECIA; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE LESION; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; BRADYCARDIA; CARDIOTOXICITY; CONSTIPATION; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DISEASE CONTROL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOXICITY; EARLY DIAGNOSIS; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HYPOTHYROIDISM; IMMUNOGLOBULIN DEFICIENCY; LIGHT CHAIN; LOW DRUG DOSE; MAINTENANCE THERAPY; MICROENVIRONMENT; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; SOMNOLENCE; SURVIVAL; TERATOGENICITY; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYTOGENETICS; EARLY DIAGNOSIS; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 77957076423     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Hirabayashi Y, Katanoda K. Comparison of time trends in multiple myeloma incidence (1973-1997) in East Asia, Europe and United States, from Cancer Incidence in Five Continents, Vols IV-VIII. Jpn J Clin Oncol 2008;38:720-721.
3. Grass S, Preuss KD, Ahlgrimm M, Fadle N, Regitz E, Pfoehler C, et al. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: A case control study. Lancet Oncol 2009;10:950-956.
4. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114:785-790.
5. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et al. Familial myeloma. N Engl J Med 2008;359:152-157.
6. Kumar L, Vikram P, Kochupillai V. Recent advances in the mangement of multiple myeloma. Natl Med J India 2006;19:80-89.
7. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78: 21-33.
8. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325-330.
9. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009;23:1545-1556.
10. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007;92:50-55.
11. Shortt CP, Gleeson TG, Breen KA, McHugh J, O'Connell MJ, O'Gorman PJ, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 2009;192:980-986.
12. Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, et al. Multiple myeloma-an update on diagnosis and treatment. Eur J Haematol 2008; 81:329-343.
13. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
14. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: Emphasis on risk factors for progression. Br J Haematol 2007;139:730-743.
15. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582-2590.
16. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
17. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420. Erratum in: J Clin Oncol 2005;23:6281.
18. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-39.
19. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009;23: 1941-1956.
20. Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009;27:4585-4590.
21. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873. Erratum in: N Engl J Med 2005;352:1163.
22. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005;106:3553-3558.
23. Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007;21:2020-2024.
24. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418-5422.
25. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324-339.
26. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-441.
27. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-89.
28. Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J, et al. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 1988;58:469-473.
29. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39.
30. Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, et al. Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi. Role of thalidomide in previously untreated patients with multiple myeloma. Expert Rev Anticancer Ther 2008;8:1569-1580.
31. Galustian C, Dalgleish A. Lenalidomide: A novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009;10:125-133.
32. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008-5014.
33. Gay F, Palumbo A. Multiple myeloma: Management of adverse events. Med Oncol 2009 July 7 (Epub ahead of print).
34. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An openlabel randomised controlled trial. Lancet Oncol 2010;11:29-37. Erratum in: Lancet Oncol 2010;11:14.
35. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-2042.
36. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008;14:795-798.
37. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009;23:449-456.
38. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-2177.
39. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124-127.
40. Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007;18:1369-1375.
41. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24: 431-436.
42. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
43. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:3435-3442.
44. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial. Lancet 2006;367:825-831.
45. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 2008;112:3107-3114.
46. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomized trial. Lancet 2007;370:1209-1218.
47. Gay F, Rajkumar SV, Jayabalan DS, Kumar S, Mark T, Disppenzieri A, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma. Blood 2009;114:abstract 2868.
48. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al; Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
49. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009;23:1964-1979.
50. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
51. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560-565.
52. Rosinol L, Cibeira MT, Martinez J, Mateos MV, Oriol A, Terol MJ, et al. Thalidomide/ dexamethasone (TD) vs bortezomib (velcade)/thalidomide/dexamethasone vs VBMCP/VBAD/velcade as induction regimens in prior autologous stem cell transplantation (SCT) in multiple myeloma (MM): Results of a phase III PETHEMA/GEM trial. Blood 2009;114:59 (abstract 130).
53. Palumbo A, Bringhen S, Rossi D, Ria R, Offidani M, Patriarca F, et al. Bortezomib, melphalan, prednisolone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. Blood 2009;114:58 (abstract 128).
54. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784-4790.
55. Durie BG. Treatment of myeloma-are we making progress? N Engl J Med 2008; 359:964-966.
56. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al; GIMEMA-Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA- Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-4465.
57. Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Ghobrial I, et al. Lenalidomide, bortezomib and dexamethasone (Rev/Vel/Dex) as front line therapy for patients with multiple myeloma (MM). Blood 2007;110:2714.
58. Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2:879-882.
59. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
60. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. Erratum in: Leukemia 2007;21:1134; Leukemia 2006;20:2220.
61. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:91-97.
62. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348: 1875-1883.
63. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. Highdose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-9233.
64. Blade J, Sureda A, Ribera JM, Mediavilla JD, Larafia JG, Palomera L, et al. High dose therapy/auto transplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: Definitive results from PETHEMA after a median follow up of 66 months. Blood 2003;102:42a (abstract 137).
65. Barlogie B, Kyle R, Anderson K, Greipp Ph, Lazarus H, Jacobson J, et al. Comparative survival in multiple myeloma with high dose therapy employing mel 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon maintenance: Results of intergroup trial S9321. Blood 2003;102:42a (abstract 135).
66. Palumbo A, Bringhen S, Petrucci MT, Rus C, Musto P, Pogliani E, et al. A prospective randomized trial of intermediate dose melphalan (100 mg/m2) versus oral melphalan/prednisolone. Blood 2003;102:984a (abstract 3661).
67. Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R, Kochupillai V. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: What predicts the outcome? Experience from a developing country. Bone Marrow Transplant 2009;43:481-489.
68. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183-196.
69. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-3146.
70. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-2654.
71. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793.
72. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502. Erratum in: N Engl J Med 2004;350:2628.
73. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis. J Natl Cancer Inst 2009;101:100-106.
74. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-3594.
75. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009;113:3383-3391.
76. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-3593.
77. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dosereduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
78. Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009;37:791-798.
79. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020-1034.
80. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163-3168.
81. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-1030.
82. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al; Inter- Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294.
83. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793.
84. Magarotto V, Palumbo A. Evolving role of novel agents for maintenance therapy in myeloma. Cancer J 2009;15:494-501.
85. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
86. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341: 1565-1571. Erratum in: N Engl J Med 2000;342:364.
87. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-2152.
88. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
89. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472.
90. McDonald RJ, Trout AT, Gray LA, Dispenzieri A, Thielen KR, Kallmes DF. Vertebroplasty in multiple myeloma: Outcomes in a large patient series. AJNR Am J Neuroradiol 2008;29:642-648.
91. Ludwig H. Prevalence, pathogenesis and treatment of anemia with erythropoietic agents in multiple myeloma. Hematol J 2005;90 (Suppl 1):10-11 (abstract F2.05).
92. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of highdose therapy and novel agents. Clin Infect Dis 2009;49:1211-1225.
93. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
94. San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008; 26:2761-2766.